Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

Clinical Infectious Diseases, 2002

1,012 citations recorded by the source corpus.

Subfields: Endocrinology, Molecular Biology, Molecular Medicine

View Paper: https://www.semanticscholar.org/paper/f803ae20771a3c8e7b936384907fb35f0f63a472

Citations in the corpus

• How to manage Pseudomonas aeruginosa infections (2018, neutral): “aeruginosa belongs to the resistance-nodulation-division (RND) family [42,43].”
• Pseudomonas aeruginosa - a phenomenon of bacterial resistance. (2009, neutral): “Its impact on the resistance to antipseudomonal antibiotics (b-lactams, fluoroquinolones, aminoglycosides and polymyxin B) is summarized in Table 4 (Livermore, 2002).”
• Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms (2009, neutral): “(A) Data for 13,999 nonduplicate isolates collected from 1993 to 2002 (178); (B) data for 37,390 isolates collected from 1997 to 2000 (132).”
• Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. (2013, neutral): “These efflux pumps can eject a wide range of antibiotics; for example, MexAB–OprM and MexXY–OprM can collectively efflux b-lactams, chloramphenicol, fluoroquinolones, macrolides, novobiocin, sulfonamides, tetracycline, and trimethoprim and aminoglycosides (Livermore, 2002; Schweizer, 2003).”
• Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. (2006, neutral): “susceptibility is not affected by this pump [126].”
• Clinical relevance of the ESKAPE pathogens (2013, neutral): “Emergence of New Delhi metallo-βlactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa. J. Clin. Microbiol. 50(2), 525–527 (2012).”
• Combination Therapy for Treatment of Infections with Gram-Negative Bacteria (2012, positive): “Although the need for definitive combination therapy is questionable, delays in initiating appropriate antimicrobial therapy for pseudomonal infections (which often consists of combination therapy) have been associated with higher mortality (27, 117, 123, 124, 157, 165, 166).”
• Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. (2006, neutral): “tiple resistance mechanisms that can be present within the pathogen concurrently [70, 71].”
• Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. (2008, neutral): “This resistance is mediated by multiple efflux pumps, which may be expressed all the time or may be upregulated by mutation (47).”